Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Adamed Pharma discovers dual 5-HT2A and 5-HT6 receptor antagonists

Sep. 13, 2019

LCGA-17 peptide shows anxiolytic and antidepressant activity in zebrafish

Sep. 13, 2019

Navitor presents data from phase I program of NV-5138

Sep. 13, 2019

Prevail Therapeutics advances development of PR-001 for Parkinson's and Gaucher's diseases

Sep. 12, 2019

Ocrelizumab in RRMS: CASTING study phase III results presented

Sep. 12, 2019

New analgesics synthesized at Daiichi Sankyo

Sep. 12, 2019

Transgenic CYP2C19 mouse as a new animal model for hyperdopaminergism-induced hyperkinesia

Sep. 12, 2019

Tiziana presents phase I results for nasal foralumab

Sep. 12, 2019

Alector begins phase II study of AL-001 for frontotemporal dementia

Sep. 10, 2019

Phase II study of bryostatin-1 in moderate to severe Alzheimer's misses primary endpoint

Sep. 10, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...